Can a weekly shot ease severe swallowing trouble in EoE?
NCT ID NCT06352073
First seen Jan 04, 2026 · Last updated May 02, 2026 · Updated 17 times
Summary
This study looks at how well dupilumab, an FDA-approved drug, works for people with severe eosinophilic esophagitis (EoE) who have narrowing of the esophagus. About 23 participants will receive weekly injections of dupilumab for one year. The goal is to see if the drug reduces inflammation and helps with swallowing, while monitoring for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.